Literature DB >> 25592098

Rheumatoid factor mediates excess serum lipoprotein(a) for independent association with type 2 diabetes in men.

Altan Onat1, Evin Ademoğlu, Günay Can, Servet Altay, Ahmet Karagöz, Bayram Köroğlu, Hüsniye Yüksel.   

Abstract

OBJECTIVE: The potential association of rheumatoid factor (RF) and lipoprotein (Lp)(a) levels, as well as with the likelihood of type 2 diabetes and hypertension, needs exploring.
METHODS: Cross-sectional associations were sought in this unselected and population-based 1539-adult cohort (age 58.8±10.6 years). RF was assayed nephelometrically. Multiple logistic regression analyses were used for covariates of RF positivity and for the latter's association with diabetes and hypertension.
RESULTS: RF-positive individuals were older, fewer current smokers, had significantly lower fasting triglycerides (by 13%), higher fibrinogen, and tended to higher sex hormone-binding globulin (SHBG) levels. Whereas, women had a similar risk profile irrespective of RF status, RF-positive men had significantly higher Lp(a). In contrast to Lp(a) being positively correlated with SHBG in RF-negative subjects (r=0.08; p=0.007), an inverse correlation existed in seropositive individuals (r=-0.32, p=0.011), suggesting the interplay of an immune complex. In regression analyses, RF positivity was associated with Lp(a) in men but not in women, [OR 1.53 (1.19; 1.96)], independent of age, SHBG, and C-reactive protein (CRP). RF positivity was further associated with diabetes [OR 1.98 (95% CI 1.11; 3.52)] in the whole sample, additively to waist circumference and CRP, major determinants of diabetes. RF-positive subjects were not significantly associated independently with hypertension.
CONCLUSION: Autoimmune activation linked to Lp(a) is mediated by the autoantibody RF in contributing to the development of type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25592098      PMCID: PMC5336962          DOI: 10.5152/akd.2014.5826

Source DB:  PubMed          Journal:  Anatol J Cardiol        ISSN: 2149-2263            Impact factor:   1.596


  37 in total

Review 1.  Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.

Authors:  Scott M Grundy; H Bryan Brewer; James I Cleeman; Sidney C Smith; Claude Lenfant
Journal:  Circulation       Date:  2004-01-27       Impact factor: 29.690

2.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Authors:  Kenneth G Saag; Gim Gee Teng; Nivedita M Patkar; Jeremy Anuntiyo; Catherine Finney; Jeffrey R Curtis; Harold E Paulus; Amy Mudano; Maria Pisu; Mary Elkins-Melton; Ryan Outman; Jeroan J Allison; Maria Suarez Almazor; S Louis Bridges; W Winn Chatham; Marc Hochberg; Catherine MacLean; Ted Mikuls; Larry W Moreland; James O'Dell; Anthony M Turkiewicz; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06-15

Review 3.  Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review.

Authors:  Lillian Barra; Janet Pope; Louis Bessette; Boulos Haraoui; Vivian Bykerk
Journal:  Rheumatology (Oxford)       Date:  2010-07-09       Impact factor: 7.580

4.  Detection of serum beta(2)-GPI-Lp(a) complexes in patients with systemic lupus erythematosus.

Authors:  Chunni Zhang; Ke Li; Beilei Shi; Xiangdong Wang; Xiaozhuan Liu; Weisong Qin; Aizhong Han; Junjun Wang
Journal:  Clin Chim Acta       Date:  2009-12-21       Impact factor: 3.786

5.  Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Authors:  Chenglong Han; Don W Robinson; Monica V Hackett; L Clark Paramore; Kathy H Fraeman; Mohan V Bala
Journal:  J Rheumatol       Date:  2006-09-01       Impact factor: 4.666

Review 6.  The influence of early life factors on the risk of developing rheumatoid arthritis.

Authors:  A N Colebatch; C J Edwards
Journal:  Clin Exp Immunol       Date:  2010-10-21       Impact factor: 4.330

7.  Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data.

Authors:  Anna Bennet; Emanuele Di Angelantonio; Sebhat Erqou; Gudny Eiriksdottir; Gunnar Sigurdsson; Mark Woodward; Ann Rumley; Gordon D O Lowe; John Danesh; Vilmundur Gudnason
Journal:  Arch Intern Med       Date:  2008-03-24

8.  Serum sex hormone-binding globulin, a determinant of cardiometabolic disorders independent of abdominal obesity and insulin resistance in elderly men and women.

Authors:  Altan Onat; Gülay Hergenç; Ahmet Karabulut; Sinan Albayrak; Günay Can; Zekeriya Kaya
Journal:  Metabolism       Date:  2007-10       Impact factor: 8.694

9.  Determination of oxidized low-density lipoproteins (ox-LDL) versus ox-LDL/beta2GPI complexes for the assessment of autoimmune-mediated atherosclerosis.

Authors:  Luis R Lopez; Tammy R Buckner; Beth L Hurley; Kazuko Kobayashi; Eiji Matsuura
Journal:  Ann N Y Acad Sci       Date:  2007-08       Impact factor: 5.691

10.  Plasma triglycerides and lipoprotein(a): inverse relationship in a hyperlipidemic Italian population.

Authors:  J P Werba; O Safa; G Gianfranceschi; S Michelagnoli; C R Sirtori; G Franceschini
Journal:  Atherosclerosis       Date:  1993-07       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.